Since its launch in 2010, the company has been adhering to the “product leading” strategy, and has enriched the company's product line through various methods such as epitaxial mergers and acquisitions, cooperative agents, independent research and development, and overseas introduction, etc., and has expanded from the narrow and single orthopedic treatment field at the beginning of the listing to the existing major treatment fields such as cardiovascular and cerebrovascular fields, skeletal muscle fields, nutritional medicine, etc., and a new pattern of multi-product-driven performance growth has gradually emerged. The company is mainly engaged in R&D, production and sales of pharmaceuticals. The company's main products include amlodipine tablets, sodium creatine phosphate for injection, ginkgo damole injections, olmesartan amlodipine tablets, edoxaban tablets, pravastatin tablets, carvastatin sodium tablets, sodium hyaluronate injections, multivitamin (12) compound vitamin (3) injections, potassium chloride sustained-release tablets, injectable potassium magnesium aspartate, sodium deoxynucleotide sodium injection (DNA), levocarnitine injection, and compound glycyrrhizinate for injection Ammonium S, cefaclor for injection, compound cefaclor capsules, calcium levofolate for injection, fluorouracil for injection, Cyclophosphamide for injection, Pingyangmycin hydrochloride for injection, silodosin capsules, etc. Corporate honors: In October 2018, Yuheng Pharmaceutical won the title of 2018 Top 100 Comprehensive Strength Industrial Enterprises in China's Chemical and Pharmaceutical Industry. In July 2018, Yuheng Pharmaceutical was listed as one of the “Top 100 Pharmaceutical Industries in China”. In June 2018, Yuheng Pharmaceutical won two awards: “2017 China's Top 100 Pharmaceutical Industry” and “2017 China Pharmaceutical Law-abiding and Honest Enterprise”. In May 2018, Yuheng Pharmaceutical won the 2018 Brand Value Assessment Enterprise Brand List, “2022 Top 100 Chinese Chemical Companies”, “Specialized and New” SMEs, “2022 Outstanding Private Enterprises in Datong City”, “2022 Outstanding Tax Contribution Award”, “Outstanding Economic Contribution Enterprise Award”, and “Outstanding Tax Contribution Enterprise Award”.
No Data